APA (7th ed.) Citation

Lee, D., Roohullah, A., Cho, B., Lee, S., Lemech, C., de Souza, P., . . . Han, J. (2022). 1197TiP A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation. Annals of Oncology, 33, S1096. https://doi.org/10.1016/j.annonc.2022.07.1320

Chicago Style (17th ed.) Citation

Lee, D.H, et al. "1197TiP A Phase I-II Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients with Advanced Solid Tumors and Dose-expansion in Patients with Non-small Cell Lung Cancer Harboring C-MET Dysregulation." Annals of Oncology 33 (2022): S1096. https://doi.org/10.1016/j.annonc.2022.07.1320.

MLA (9th ed.) Citation

Lee, D.H, et al. "1197TiP A Phase I-II Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients with Advanced Solid Tumors and Dose-expansion in Patients with Non-small Cell Lung Cancer Harboring C-MET Dysregulation." Annals of Oncology, vol. 33, 2022, p. S1096, https://doi.org/10.1016/j.annonc.2022.07.1320.